Analysts expect United Therapeutics Co. (NASDAQ:UTHR) to post $372.32 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for United Therapeutics’ earnings, with estimates ranging from $332.50 million to $412.00 million. United Therapeutics reported sales of $445.50 million during the same quarter last year, which would suggest a negative year over year growth rate of 16.4%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 24th.

On average, analysts expect that United Therapeutics will report full year sales of $1.53 billion for the current financial year, with estimates ranging from $1.45 billion to $1.60 billion. For the next year, analysts forecast that the business will post sales of $1.22 billion, with estimates ranging from $1.11 billion to $1.42 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The firm had revenue of $444.50 million during the quarter, compared to analyst estimates of $368.63 million. During the same quarter last year, the business posted $4.37 EPS. The company’s revenue was up .0% on a year-over-year basis.

UTHR has been the subject of a number of recent analyst reports. Wedbush raised their price objective on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. Zacks Investment Research lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Sunday, July 15th. Credit Suisse Group lifted their target price on shares of United Therapeutics from $104.00 to $107.00 and gave the company a “neutral” rating in a research note on Tuesday, July 10th. Standpoint Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Finally, TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research note on Thursday, August 16th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $138.86.

United Therapeutics stock traded down $2.88 during midday trading on Wednesday, reaching $122.95. The stock had a trading volume of 317,191 shares, compared to its average volume of 327,836. United Therapeutics has a twelve month low of $100.57 and a twelve month high of $152.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. The firm has a market capitalization of $5.48 billion, a price-to-earnings ratio of 11.29, a P/E/G ratio of 28.40 and a beta of 1.21.

In other news, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total transaction of $419,191.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the transaction, the director now owns 1,555 shares in the company, valued at approximately $185,045. The disclosure for this sale can be found here. Insiders have sold a total of 4,860 shares of company stock valued at $611,161 in the last three months. Company insiders own 8.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in UTHR. Acadian Asset Management LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at $129,555,000. First Trust Advisors LP raised its holdings in United Therapeutics by 36.3% in the 2nd quarter. First Trust Advisors LP now owns 684,956 shares of the biotechnology company’s stock worth $77,503,000 after acquiring an additional 182,409 shares during the period. BlackRock Inc. raised its holdings in United Therapeutics by 2.3% in the 2nd quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock worth $568,925,000 after acquiring an additional 115,073 shares during the period. Greylin Investment Mangement Inc. raised its holdings in United Therapeutics by 206.7% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 118,703 shares of the biotechnology company’s stock worth $13,431,000 after acquiring an additional 80,006 shares during the period. Finally, Andra AP fonden bought a new position in United Therapeutics in the 2nd quarter worth $8,679,000. Institutional investors and hedge funds own 95.67% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.